摘要
目的研究对氧磷脂酶-1(PON1)活性与2型糖尿病大中血管及微血管病变的关系及丙二醛(MDA)水平的变化。方法用紫外分光光度法测定正常对照组(NC),2型糖尿病组(DM),2型糖尿病血管并发症组血清PON1活性及MDA水平。结果PON1活性在各组分别为:正常对照组(163.84±62.98)kU/L,2型糖尿病组(118.87±30.38)kU/L,并发冠心病组(DMCHD)(95.83±23.76)kU/L,并发脑梗死组(DMCI)(94.46±24.36)kU/L,并发肾病组(DN)(106.93±20.21)kU/L,并发肾病视网膜病变组(DNDR)(100.13±24.42)kU/L(P<0.01);MDA水平在各组分别为:NC组(3.48±0.50)μmol/L,DM组(4.02±0.75)μmol/L,DMCHD组(4.67±0.74)μmol/L,DMCI组(4.55±1.39)μmol/L,DN组(3.95±0.62)μmol/L,DNDR组(4.30±0.43)μmol/L(P<0.01)。结论与正常对照组相比,2型糖尿病组PON1活性降低,MDA水平升高;血管并发症组PON1活性更低而MDA水平进一步升高,说明2型糖尿病的脂质过氧化增加,血清PON1活性下降,并参与2型糖尿病及血管并发症的发生。
Objective To investigate the association of variation of paraoxonase (PON1) activity with the diabetic vascular complications. Methods PON1 activity was determined with spectrophotography in type two diabetes mellitus(DM) patients,DM with vascular complications patients and normal control subjects. Results PON1 activity was(163.84±62.98) kU/L in normal control group(NC), in DM group was (118.87 ± 30.38) kU/L, in DM with coronary heart disease group(DMCHD) was (95.83± 23.76) kU/L, in diabetes mellitus with cerebral infarction group was (94.46 ± 24.36) kU/L, in diabetic nephropathy(DN) group was (106.93 ± 20.21) kU/L, and in diabetic nephropathy diabetic retinopathy(DNDR) group was (100.13 ± 24.42) kU/L( P 〈0.01). MDA concentration was (3.48±0.50) μmol/L in NC group, in DM group was (4.02±0.75) μmol/L, in DMCHD group was (4.67±0.74) μmol/L, in DMCI group was (4.55±1.39) μmol/L, in DN group was (3.95±0.62) μmol/L, and in DNDR group was (4.30±0. 43) μmol/L( P 〈0.01). Conclusion PON1 activity of DM patients and DM with vascular complication patients was significantly lower than that of control subjects,while MDA level increased. Further more, PON1 activity of DM with vascular complications was lower than that of DM patients. It signifies that decreased serum PON1 activity promoted the development of diabetic vascular complications.
出处
《临床荟萃》
CAS
北大核心
2006年第7期465-467,共3页
Clinical Focus
基金
河南省科技攻关基金资助项目(0424410098)
关键词
糖尿病
2型
糖尿病发症
磷脂酶类
脂质过氧化作用
diabetes mellitus,type 2
diabetes complications
phospholipases
lipid peroxidation